RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
LANGFORD, BC, July 2, 2025 /CNW/ - After months of anticipation, Ramen Arashi Langford will officially open its doors on Tuesday, July 9th, bringing authentic...
GREATER DES MOINES, Iowa, July 2, 2025 /PRNewswire/ -- The World Food & Music Festival presented by Veridian Credit Union has announced vendors, merchants and...
The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy
WASHINGTON, July 2,...
TIANSHUI, China, July 2, 2025 /PRNewswire/ -- Reporters representing media outlets in Cambodia, Japan, South Korea, Myanmar, Morocco, Thailand, and Vietnam recently completed a week-long...
PARK CITY, UTAH, July 01, 2025 (GLOBE NEWSWIRE) -- EQV Ventures Acquisition Corp. II (the “Company”), a special purpose acquisition company sponsored by an affiliate of the EQV Group, and formed for the purpose of entering into a business combination with one or more businesses, announced today the pricing of its initial public offering of 42,000,000 units, upsized from 35,000,000 units, at a price of $10.00 per unit. The units are expected to be listed on the New York Stock Exchange (“NYSE”) and begin trading tomorrow, July 2, 2025, under the ticker symbol “EVACU.”
Live Shopping App Palmstreet Launches Collectibles Market with Coveted Labubu Resellers and Daily Prize Campaign
MENLO PARK, Calif., July 1, 2025 /PRNewswire/ -- Palmstreet, the...
Brand Rooted in Rock Music Celebrates Heavy Metal Legends and Supports Charitable Causes
TEMPE, Ariz., July 1, 2025 /PRNewswire/ -- Dixxon Flannel Co. is thrilled...
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.